Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.74 – $0.81
Volume76,092
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ICCM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ICCM.
Recent news
Company coverage with links to the original publishers.
Kyntra Bio reported a quarterly loss of $3.42 per share, beating consensus estimates of $3.66 loss, representing a 6.56% earnings surprise. However, revenues of $1.76 million missed estimates by 10.38%. The stock has declined 60.8% year-to-date versus the S&P 500's 10.5% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
HeartFlow (HTFL) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.10 loss, with a 70% earnings surprise. Revenue of $72.86 million exceeded expectations by 11.92%. The stock has gained 102.7% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Natera (NTRA) reported a quarterly loss of $0.39 per share, significantly worse than the consensus estimate of $0.17 loss, representing a -129.41% earnings surprise. While the company beat revenue expectations at $793.98 million versus estimates, it has only surpassed EPS estimates once in the last four quarters. The stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting underperformance ahead despite the stock's 70.7% year-to-date gain.
IceCure Medical Ltd. (NASDAQ: ICCM) announced a $5.5 million private placement of 1.83 million ordinary shares and warrants priced at $3.00 per share, representing a premium to the previous closing price. The offering is expected to close on June 18, 2026, with proceeds intended for working capital and general corporate purposes. The company also agreed to amend previously issued warrants to reduce their exercise price from $16.50 to $3.00 per share, subject to shareholder approval.
IceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation systems following FDA marketing authorization in October 2025. The growth is driven by FDA clearance, clinical guideline support from the American Society of Breast Surgeons, increased physician demand demonstrated at major medical conferences, and growing patient awareness through media coverage. The company believes it is in the early stages of a significant commercial opportunity in the U.S. market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.